Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2025 | $3.00 | Buy | Roth Capital |
| 11/17/2025 | Outperform | Leerink Partners | |
| 10/9/2025 | $7.00 | Outperform | Oppenheimer |
| 8/8/2025 | $3.00 | Buy | B. Riley Securities |
| 6/18/2024 | Outperform → Perform | Oppenheimer | |
| 4/30/2024 | $9.00 | Buy | B. Riley Securities |
| 4/29/2024 | $9.00 | Buy | H.C. Wainwright |
| 4/5/2024 | $8.00 | Outperform | Wedbush |
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
Roth Capital initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $3.00
Leerink Partners initiated coverage of Ovid Therapeutics with a rating of Outperform
Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $7.00
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Oppenheimer CNS & Neuro-Muscular Summit – Wednesday, June 10 at 3:45 pm ETH.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference – Monday, June 15 A webcast of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. "Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation," said Meg Alexander, President and Chief Executive Officer, Ovid Therapeutics. "Her pioneering work in ion channel biology has fundamentally advanced our understanding of disease biology and enabled the develop
Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studiesAnnounced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanismStrengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participati
8-K - Ovid Therapeutics Inc. (0001636651) (Filer)
SCHEDULE 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SCHEDULE 13G - Ovid Therapeutics Inc. (0001636651) (Subject)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
4 - Ovid Therapeutics Inc. (0001636651) (Issuer)
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. "Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation," said Meg Alexander, President and Chief Executive Officer, Ovid Therapeutics. "Her pioneering work in ion channel biology has fundamentally advanced our understanding of disease biology and enabled the develop
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSafety and tolerability results are supportive of further development and appear to be preferable relative to marketed anti-seizure medicines (ASMs)Ovid plans to advance OV329 into a Phase 2a study in d
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)
SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)